title: NK/T-cell lymphomas in children.
abstract: In children, T and NK-cell lymphomas are uncommon in Western Countries. While there has been significant experience treating T-cell lymphoblastic lymphoma (T-LBL) and anaplastic large cell lymphoma (ALCL), other subtypes are very rarely encountered and there are no standard approaches to their management. There are many challenges in defining optimal therapy for many of these diseases but recent progress in elucidating their biology has led to new molecular insights and identified interesting targets for novel drug discovery. In this review, we discuss these disorders in children, how they are approached therapeutically and what lies on the horizon with respect to novel treatment approaches.
authors.affiliation: Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
authors.forename: Catherine
authors.initials: C
authors.lastname: Lai
authors.forename: Kieron
authors.initials: K
authors.lastname: Dunleavy
mesh_terms: D018943:Anthracyclines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D055611:Natural Killer T-Cells / Q000187:drug effects* / Q000473:pathology; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents